(INMD) InMode - Ratings and Ratios

InMode Ltd (NASDAQ:INMD) is a global leader in the development of innovative, minimally invasive and non-invasive aesthetic medical solutions. The company specializes in proprietary radiofrequency (RF) technologies, including RF-assisted lipolysis and deep subdermal fractional RF, to address a wide range of aesthetic and wellness needs. Its product portfolio includes systems for liposuction with simultaneous skin tightening, body and facial contouring, ablative skin rejuvenation, and womens health applications. In addition, InMode offers non-invasive solutions for permanent hair reduction, facial rejuvenation, wrinkle reduction, cellulite treatment, and vascular lesion removal. The company also innovates in hands-free technologies for skin tightening, fat reduction, and muscle stimulation, catering to both aesthetic and therapeutic markets.

Headquartered in Yokneam, Israel, InMode operates a global distribution network spanning the U.S., Canada, Europe, Asia, and Australia. The company, formerly known as Invasix Ltd., was renamed InMode Ltd. in 2017 and has established itself as a key player in the medical aesthetics industry. With a market capitalization of $895.51 million and a trailing P/E of 6.59, InMode demonstrates strong profitability with an ROE of 28.38%. The stock currently trades at $14.57, below its SMA 20 ($15.04) and SMA 50 ($17.13), signaling a near-term downtrend. The ATR of 0.93 reflects moderate volatility. Looking ahead, InModes focus on R&D and expanding its product portfolio positions it for growth in a competitive market.